| Description |
Recombinant Human EPHA10 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Glu34-Ala565. |
| Purity |
> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
| Accession |
Q5JZY3 |
| Target Symbol |
EPHA10 |
| Synonyms |
EphA10; FLJ16103; FLJ33655; MGC43817 |
| Species |
Human |
| Expression System |
HEK293 |
| Tag |
C-His |
| Expression Range |
Glu34-Ala565 |
| Mol. Weight |
The protein has a predicted MW of 58.8 kDa. Due to glycosylation, the protein migrates to 60-70 kDa based on Tris-Bis PAGE result. |
| Form |
Lyophilized |
| Formulation |
Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Endotoxin |
Less than 1EU per ug by the LAL method. |
| Activity |
Immobilized Human EPHA10, His Tag at 1ug/ml (100ul/well) on the plate. Dose response curve for Human/Cynomolgus EFNA3, hFc Tag with the EC50 of 0.24ug/ml determined by ELISA. Contact us for detailed testing images. |
| Storage |
Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipping |
Shipped at ambient temperature. |
| Gene Background |
EphA10 (erythropoietin-producing hepatocellular carcinoma receptor A10) is a catalytically defective receptor protein tyrosine kinase in the ephrin receptor family.EphA10 was elevated and higher in tumor tissues than in normal tissues in some cancer types, including pancreatic cancer.EphA10 silencing reduced the proliferation, migration, and adhesion of MIA PaCa-2 and AsPC-1 pancreatic cancer cells. EphA10 plays a pivotal role in the tumorigenesis of pancreatic epithelial cells and is a novel therapeutic target for pancreatic cancer. |
